Related introduction of Linvoseltamab: What kind of medicine is it used to treat?

Linvoseltamab (rivosetantumab) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager indicated for the treatment of relapsed or refractory multiple myeloma (R/RMM), specifically adult patients with R/R MM who have received at least four prior therapies, including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies. Multiple myeloma is a blood cancer characterized by the proliferation of cancerous plasma cells (multiple myeloma cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues, and cause potentially life-threatening organ damage.

Linvoseltamab is a treatment designed to bridge B cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to promote T cell activation and cancer cell killing. The FDA's accelerated approval of linvoseltamab is based on data from the pivotal Phase 1/2 LINKER-MM1 trial, which showed that patients (n=80) experienced 70% of patients as determined by an independent review committee Observational response rate (ORR), with 45% achieving complete response (CR) or better; and median time to first response 0.95 months (range: 0.5 to 6 months); median duration of response (DoR) not reached (95% confidence interval [CI]: 12 months to not estimable). Among responders with a median follow-up of 13 months, the estimated DoR was 89% (95% CI: 77 to 95 months) at 9 months and 72% (95% CI: 54 to 84 months) at 12 months.

Linvoseltamab is administered by intravenous infusion according to an ascending dosing schedule (once weekly, then every two weeks at Week 14, then every four weeks at Week 24, depending on response). Common adverse reactions (≥20%) include musculoskeletal pain, cytokine release syndrome, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea.

Reference materials:https://en.wikipedia.org/wiki/Linvoseltamab